Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG).
Kastritis E, Katodritou E, Badelita S, Bila J, Seval GC, Cvetkovic Z, Coriu D, Spanoudakis E, Dalampira D, Sretenovic A, Sevastoudi A, Bojan A, Mitrovic M, Danaila C, Gavriatopoulou M, Roussou M, Charalampous C, Terpos E, Beksac M, Dimopoulos MA. Kastritis E, et al. Among authors: danaila c. Leuk Lymphoma. 2024 Aug 14:1-4. doi: 10.1080/10428194.2024.2391900. Online ahead of print. Leuk Lymphoma. 2024. PMID: 39141607 No abstract available.
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larrán A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Döhner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, García-Gutierrez V, Heidel FH, Illés A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wölfler A, Cirici BX, Klade C. Kiladjian JJ, et al. Among authors: danaila cd. Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4. Ann Hematol. 2024. PMID: 38438627 Free PMC article.
Design and implementation of a humanitarian cancer care programme for Ukrainian refugees in Moldova and Romania.
Vulpe H, Minzatean A, Tocino I, Baltaga R, Kacso G, Oprea C, Ciobanu V, Brenister S, Tomuleasa C, Ricu G, Mindruta-Stratan R, Danaila C, Iancu D, Circiumari L, Teglas C, Lonnback L, Nazaria V, Wagner U, Ciubotaru E, Minzatean N, Jitaru C, Polozov S, Matiushenko I, Uzlova A, Sullivan R, Magidson S. Vulpe H, et al. Among authors: danaila c. Lancet Oncol. 2024 Mar;25(3):289-291. doi: 10.1016/S1470-2045(23)00629-0. Epub 2024 Jan 30. Lancet Oncol. 2024. PMID: 38307101 No abstract available.
Combined flow cytometry natural killer immunophenotyping and KIR/HLA-C genotyping reveal remarkable differences in acute myeloid leukemia patients, but suggest an overall impairment of the natural killer response.
Cianga VA, Rusu C, Pavel-Tanasa M, Dascalescu A, Danaila C, Harnau S, Aanei CM, Cianga P. Cianga VA, et al. Among authors: danaila c. Front Med (Lausanne). 2023 Mar 7;10:1148748. doi: 10.3389/fmed.2023.1148748. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36960339 Free PMC article.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.
Deak D, Pop C, Zimta AA, Jurj A, Ghiaur A, Pasca S, Teodorescu P, Dascalescu A, Antohe I, Ionescu B, Constantinescu C, Onaciu A, Munteanu R, Berindan-Neagoe I, Petrushev B, Turcas C, Iluta S, Selicean C, Zdrenghea M, Tanase A, Danaila C, Colita A, Colita A, Dima D, Coriu D, Einsele H, Tomuleasa C. Deak D, et al. Among authors: danaila c. Front Immunol. 2019 Dec 20;10:2856. doi: 10.3389/fimmu.2019.02856. eCollection 2019. Front Immunol. 2019. PMID: 31921126 Free PMC article. Review.
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Mateos MV, et al. N Engl J Med. 2018 Feb 8;378(6):518-528. doi: 10.1056/NEJMoa1714678. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231133 Free article. Clinical Trial.
26 results